The GLP-1 era is rewriting what “support” means
GLP-1 medications have moved metabolic health into the mainstream, and that shift is now influencing the supplement aisle as much as it’s shaping clinical conversations. As more consumers adopt GLP-1 therapies for weight management, brands are being pushed to think beyond generic “protein” messaging and build solutions that match the real-world needs that show up once appetite changes. Smaller meals, inconsistent protein intake, and digestive discomfort can make it harder for users to hit daily targets, even when motivation is high.
At the same time, the most commercially important insight for brands is this: weight loss is not the only outcome that matters. Many users are actively looking for ways to preserve lean mass and support structural health while they reduce body weight. That creates a clear opening for collagen, but only if collagen can be positioned with a stronger nutritional rationale than beauty alone.
Why collagen needs a smarter digestion story
Collagen has become a staple ingredient because it’s familiar, easy to formulate, and widely associated with hair, skin, nails, joints, and mobility. But in the GLP-1 context, the conversation is evolving. Collagen is being reframed as a protein source that could play a structural role during periods of reduced intake, when muscle and bone support become more top-of-mind.
The challenge is that consumer demand has matured. Today’s metabolic-health shopper wants evidence and mechanism, not a broad promise. That’s where the digestion narrative becomes central: collagen only becomes truly useful when it’s broken down into peptides that the body can absorb and utilize efficiently. If digestion is compromised, or if the protein isn’t being broken down as well as it could be, the value proposition weakens.
Pepzyme AG is being positioned as a direct response to that gap, offering a formulation approach that focuses less on “add more collagen” and more on “help the collagen you already use perform better.”
What Pepzyme AG adds to the formulation conversation
Pepzyme AG is a proteolytic enzyme blend designed to support collagen breakdown during digestion and increase the release of low-molecular-weight peptides. In practical terms, the story is simple: it aims to help collagen turn into smaller, more bioactive fragments that are easier for the body to use.
The ingredient’s key claim is that it enhances collagen digestion under a standardized, widely recognized in vitro digestion model. The relevance for product developers is not academic. Standardized digestion methods have become increasingly important because they allow brands to speak about digestion performance in a way that’s more consistent and comparable than older “in-house” models. For marketing teams, that translates into a clearer scientific backbone for premium positioning.
Beyond improved breakdown, the more commercially distinctive angle is peptide function. Pepzyme AG is associated with increased release of peptides that demonstrate improved DPP-IV inhibitory activity in vitro. That matters because DPP-IV is the enzyme that breaks down endogenous GLP-1 in the body. While in vitro activity is not the same as a clinical outcome, it provides a mechanistic narrative that aligns with the direction of the market: supporting the body’s natural GLP-1 activity and complementing the broader metabolic-health lifestyle consumers are building around therapy.
From “beauty collagen” to “metabolic collagen”
For collagen brands, the strategic opportunity here is positioning. The category has long relied on familiar claims and lifestyle visuals, but GLP-1 is changing buying behaviour. Consumers are scrutinizing labels, looking for functional stacks, and favouring products that feel designed for their new routines. In that context, collagen can shift from a general wellness add-on to a functional ingredient that supports both structural needs and metabolic priorities.
Pepzyme AG is being marketed as the bridge that makes this repositioning easier. Rather than asking brands to abandon collagen’s traditional identity, it allows them to evolve it: collagen becomes less about vague “support” and more about digestive performance, peptide delivery, and formulation credibility. It also gives brands a more defensible answer when consumers ask the most important question in modern nutrition: why this product, and why now?
The biggest takeaway for the functional ingredient community is that GLP-1 users represent more than a fast-growing segment. They represent a new standard for how products must be built and explained. Collagen brands that adapt to this standard with science-led formulation upgrades will be better positioned to stand out in a crowded market where differentiation increasingly depends on mechanism, not marketing.
